Asian Pacific Journal of Tropical Medicine

REVIEW ARTICLE
Year
: 2021  |  Volume : 14  |  Issue : 10  |  Page : 433--439

Favipiravir and its potentials in COVID-19 pandemic: An update


Dao Ngoc Hien Tam1, Ahmad T Qarawi2, Mai Ngoc Luu3, Morgan Turnage4, Linh Tran5, Gehad Mohamed Tawfik6, Le Huu Nhat Minh7, Nguyen Tien Huy8, Tatsuo Iiyama9, Kyoshi Kita8, Kenji Hirayama8 
1 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Asia Shine Trading & Service CO. LTD., Ho Chi Minh City 700000, Vietnam
2 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Essen Healthcare, Bronx, New York 10461 USA
3 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
4 American University of the Caribbean, Cupecoy, Sint Maarten
5 Institute of Fundamental and Applied Sciences, Duy Tan University, Ho Chi Minh City 700000; Faculty of Natural Sciences, Duy Tan University, Da Nang City 550000, Vietnam
6 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
7 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Methodist Hospital, Merrillville, Indiana, United States
8 School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
9 Department of International Trials, Center of Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan

Correspondence Address:
Nguyen Tien Huy
School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523
Japan

The COVID-19 pandemic has caused millions of deaths and hundreds of millions of confirmed infections worldwide. This pandemic has prompted researchers to produce medications or vaccines to reduce or stop the progression and spread of this disease. A variety of previously licensed and marketed medications are being tested for the treatment and recurrence of SARS-CoV2, including favipiravir (Avigan). Favipiravir was recognized as an influenza antiviral drug in Japan in 2014, and has been known to have a potential in vitro activity against SARS-CoV-2, in addition to its broad therapeutic safety scope. Favipiravir was recently approved and officially used in many countries worldwide. Our review provides insights and up-to-date knowledge of the current role of favipiravir in the treatment of COVID-19 infection, focusing on pre-clinical and ongoing clinical trials, evidence of its efficacy against SARS-CoV-2 in COVID-19, side effects, anti-viral mechanism, and the pharmacokinetic properties of the drug in the treatment of COVID-19. Due to its teratogenic effects, favipiravir cannot be offered to expectant or pregnant mothers. The practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application.


How to cite this article:
Tam DN, Qarawi AT, Luu MN, Turnage M, Tran L, Tawfik GM, Minh LH, Huy NT, Iiyama T, Kita K, Hirayama K. Favipiravir and its potentials in COVID-19 pandemic: An update.Asian Pac J Trop Med 2021;14:433-439


How to cite this URL:
Tam DN, Qarawi AT, Luu MN, Turnage M, Tran L, Tawfik GM, Minh LH, Huy NT, Iiyama T, Kita K, Hirayama K. Favipiravir and its potentials in COVID-19 pandemic: An update. Asian Pac J Trop Med [serial online] 2021 [cited 2021 Dec 5 ];14:433-439
Available from: https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=10;spage=433;epage=439;aulast=Tam;type=0